Chapter 7 — Case Study 2: The Asymmetric Synthesis Revolution and the 2001 Nobel Prize

"In 1968 we knew chirality mattered. In 1980 we had the first generation of chiral catalysts. In 2001 the Nobel Committee recognized asymmetric catalysis as one of the great advances of 20th-century chemistry. Today, asymmetric synthesis underpins the pharmaceutical industry's production of single-enantiomer drugs — saving lives, money, and waste." — paraphrase from a process chemistry textbook

This case study traces the development of asymmetric catalysis — the chemistry that taught chemists how to selectively produce one enantiomer of a chiral molecule from achiral or racemic starting materials. The 2001 Nobel Prize in Chemistry went to William Knowles, Ryoji Noyori, and K. Barry Sharpless for this body of work, and the impact on industry has been enormous.

The pre-asymmetric world

Before the 1970s, most industrial syntheses of chiral molecules produced racemic mixtures. Two main strategies for getting a single enantiomer:

  1. Resolution: separate the two enantiomers from the racemate. Methods: - Diastereomeric salt formation with a chiral resolving agent (Pasteur's method). - Chiral chromatography (very expensive at industrial scale). - Enzymatic resolution (use an enzyme that selectively reacts with one enantiomer).

  2. Chiral pool synthesis: start from an enantiomerically pure natural compound (like L-amino acids, D-sugars) and build the target compound while preserving the chirality.

Both have severe limitations. Resolution wastes 50% of the substrate. Chiral pool requires the right starting material to be commercially available.

The breakthrough idea: use a chiral catalyst that builds the desired enantiomer directly from achiral starting material.

The key idea: asymmetric induction

A chiral catalyst is itself chiral — it has an asymmetric active site that distinguishes the two faces of a prochiral substrate. When the substrate approaches the catalyst, one orientation is preferred (lower-energy transition state), and the product is enriched in one enantiomer.

Schematically: - Prochiral substrate + chiral catalyst → one enantiomer of product (with high ee)

The catalyst is regenerated, so a small amount can produce many turnovers — orders of magnitude more product than catalyst. This is what makes asymmetric catalysis economically viable.

Three landmark methods

1. Knowles' asymmetric hydrogenation (1968)

William Knowles at Monsanto developed a chiral rhodium catalyst with a chiral phosphine ligand (DIPAMP, 1,2-bis(o-anisylphenylphosphino)ethane). The catalyst reduces prochiral alkenes (with two different substituents on each sp² carbon) to alkanes with high ee.

The first commercial application: L-DOPA synthesis for Parkinson's disease (1974). Before Knowles' method, L-DOPA was made by chemical resolution — wasting 50% of every batch. After Knowles', it was made directly by asymmetric hydrogenation in one step from a prochiral alkene precursor.

This was the first commercial enantioselective synthesis in pharmaceutical history. Knowles received the 2001 Nobel Prize for this work.

2. Noyori's hydrogenation of ketones (1980s onward)

Ryoji Noyori (Nagoya, Japan) developed chiral BINAP-Ru complexes that reduce a wider range of substrates: not just alkenes (Knowles), but also β-keto esters, ketones, imines, and others.

Specifically, the Noyori asymmetric hydrogenation of β-keto esters gives β-hydroxy esters in >95% ee. This is used industrially for many drug syntheses.

Noyori also developed asymmetric transfer hydrogenation (using HCOOH or 2-propanol as H source instead of H₂) — easier to use industrially because no high-pressure H₂ gas is needed.

His catalysts have been used in the synthesis of many drugs, fragrances, and fine chemicals. Noyori received the 2001 Nobel Prize.

3. Sharpless' asymmetric methods (1980s onward)

K. Barry Sharpless (originally at MIT, then Scripps) developed several asymmetric reactions:

  • Sharpless asymmetric epoxidation (1980): chiral Ti-DET (diethyl tartrate) complex converts allylic alcohols to chiral epoxides. Used for many natural product syntheses.
  • Sharpless asymmetric dihydroxylation (1988): OsO₄ + chiral cinchona alkaloid ligand gives chiral diols from prochiral alkenes. Reagent kits (AD-mix-α and AD-mix-β) are sold pre-mixed.
  • Sharpless asymmetric aminohydroxylation (1996): similar, gives β-amino alcohols.

Sharpless received the 2001 Nobel Prize, then a second Nobel in 2022 for click chemistry.

The 2001 Nobel Prize

The award citation read: "for their work on chirally catalysed hydrogenation reactions [Knowles, Noyori] and oxidation reactions [Sharpless]." Awarded to: - William S. Knowles (Monsanto, US) - Ryoji Noyori (Nagoya University, Japan) - K. Barry Sharpless (Scripps, US)

Specifically, this Nobel was for the development of catalytic asymmetric methods — using small amounts of catalyst to produce large amounts of single-enantiomer product. The catalysts they developed are now in industrial use worldwide.

The industrial impact

Today, about 60% of the top 200 pharmaceutical drugs are chiral, and about 55% are marketed as single enantiomers (up from 10% in 1990). Major industrial asymmetric syntheses include:

(S)-Naproxen (anti-inflammatory)

Asymmetric hydrogenation of an α-arylacrylic acid using a Ru-BINAP catalyst gives (S)-naproxen in 96% ee. The (R) form would be hepatotoxic, so single-enantiomer purity is critical. Annual production: ~2,000 tons.

Atorvastatin (Lipitor)

The blockbuster cholesterol-lowering drug has two stereocenters, both (R). The synthesis uses enzymatic asymmetric reductions to install both. Atorvastatin sold over $130 billion (2003-2010), making it the highest-selling drug in history. The asymmetric synthesis is essential.

Sitagliptin (Januvia)

An anti-diabetic drug developed by Merck (2006). Originally synthesized using a stoichiometric chiral auxiliary. In 2010, Merck and Codexis developed a much greener route using an engineered transaminase enzyme + asymmetric hydrogenation, winning the 2010 EPA Green Chemistry Award. We'll see this case in Ch 40.

L-DOPA

Knowles' original target, still produced this way for Parkinson's treatment. ~250 tons/year globally.

Esomeprazole (Nexium)

The (S) form of omeprazole. AstraZeneca's asymmetric oxidation (using a chiral catalyst) provides the pure (S) form. Peak sales: ~$5 billion/year.

Diltiazem (cardiovascular drug)

Made by asymmetric epoxide ring-opening using a chiral salen-Co catalyst (Jacobsen).

The commercial value of asymmetric catalysis runs into the tens of billions of dollars per year. The 2001 Nobel Prize was among the most economically impactful chemistry prizes ever awarded.

Modern asymmetric methods

The field continues to evolve:

Organocatalysis (Nobel 2021)

Benjamin List and David MacMillan showed that small organic molecules — proline, MacMillan's imidazolidinone — can act as chiral catalysts without metals. Cheaper, greener, often equally selective.

Biocatalysis

Engineered enzymes (transaminases, ketoreductases, lipases) are used for many industrial asymmetric syntheses. Often greener than metal catalysis (water solvent, mild conditions).

Photoredox catalysis (Ch 40)

Combining chiral catalysts with photoredox initiation gives access to new asymmetric reactions under mild visible-light conditions.

Flow chemistry

Combining asymmetric catalysis with continuous flow gives faster, more controllable reactions.

What Chapter 7 has taught

You now have the vocabulary to read the Nobel citations: "asymmetric hydrogenation of prochiral substrates to give enantiomerically enriched products" translates to "reducing a molecule with two faces to preferentially give one of two possible enantiomers, with more of one than the other."

You understand: - Why this matters (biological receptors are chiral). - What "enantiomerically enriched" means (high ee). - Why a chiral catalyst can preferentially produce one enantiomer (asymmetric induction).

Chapter 8 will explain the mechanism-level details of how asymmetric reactions work. Chapter 36 covers asymmetric oxidation and reduction in detail. Chapter 37 covers the organometallic chemistry. Chapter 38's capstone uses asymmetric methods. Chapter 40 returns to industrial green chemistry.

Take-home

  • Asymmetric catalysis uses chiral catalysts to selectively produce one enantiomer from achiral or prochiral substrates.
  • 2001 Nobel Prize in Chemistry awarded to Knowles (asymmetric hydrogenation), Noyori (asymmetric ketone hydrogenation), Sharpless (asymmetric epoxidation, dihydroxylation).
  • Knowles' L-DOPA process (1974) was the first commercial enantioselective drug synthesis.
  • Industrial impact: 60% of top drugs are chiral; 55% sold as single enantiomers (up from 10% in 1990).
  • Major drugs made by asymmetric catalysis: naproxen, atorvastatin, sitagliptin, L-DOPA, esomeprazole, diltiazem, ibuprofen (sometimes), and many more.
  • Modern extensions: organocatalysis (Nobel 2021), biocatalysis, photoredox, flow chemistry.
  • Chapter 7's stereochemistry vocabulary is the foundation for understanding all of this. Asymmetric synthesis is an entire field built on the principle of one stereocenter at a time.

Further reading

  • Knowles, W. S. (2002). "Asymmetric hydrogenations (Nobel Lecture)." Angewandte Chemie International Edition, 41, 1998-2007.
  • Noyori, R. (2002). "Asymmetric catalysis: Science and opportunities (Nobel Lecture)." Angewandte Chemie International Edition, 41, 2008-2022.
  • Sharpless, K. B. (2002). "Searching for new reactivity (Nobel Lecture)." Angewandte Chemie International Edition, 41, 2024-2032.
  • Blaser, H.-U.; Federsel, H.-J. (eds.) (2010). Asymmetric Catalysis on Industrial Scale: Challenges, Approaches and Solutions (2nd ed.). Wiley-VCH.
  • Anastas, P. T.; Eghbali, N. (2010). "Green chemistry: Principles and practice." Chem. Soc. Rev. 39, 301-312.